AbbVie hands United a record $350M payoff for a speedy FDA review voucher

John Carroll

The cost of a priority for the FDA keeps going up. is forking over a $ 350 million to acquire a from Therapeutics, giving them an option at shaving four months off the agency's standard 10-month review process.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS